ClinicalTrials.gg
RecruitingNCT07208331TELE-CVRMUpdated Oct 9, 2026

Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway for Cardiovascular Risk Management

An observational study in Atherosclerotic Cardiovascular Disease (ASCVD), Hypertension and Dyslipidemia, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
750
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Atherosclerosis with a site in Netherlands — 15 open to participants now, 24 under way, 9 of them phase 3. Atherosclerosis · Netherlands.

Planned enrollment
12th of 30
750 · median 247
Started
2026
with 4 others
Observational
30 of 102
8 open now
Primary completion
2028-03
later than 14 of 23 live
Registered
97th of 102
by date
Lead sponsor
8 of 102
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 102 studies in Atherosclerosis with a site in Netherlands, this one is the 12th largest by planned enrollment of the 30 observational ones that give a count, is one of 5 that started in 2026, is one of 30 observational ones, reaches primary completion later than 14 of the 23 other live ones, and was the 97th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

15 of the 102 studies in Atherosclerosis with a site in Netherlands are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Atherosclerosis with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate the implementation of a structured, digital, nurse-led, remote monitoring care pathway for cardiovascular risk management (CVRM). Participants will receive this care as part of routine clinical practice. In addition to standard follow-up, participants will complete questionnaires on quality of life, medication adherence, system usability, and patient satisfaction.

Read the detailed description

CVRM is essential for patients at increased risk of cardiovascular disease (CVD) as well as for those with established atherosclerotic cardiovascular disease (ASCVD). Monitoring blood pressure and lipid profiles is crucial to achieving guideline-recommended targets. However, many patients fail to reach these targets despite the availability of effective therapies, resulting in an increased risk of recurrent events. Meanwhile, the burden of CVD continues to rise, creating significant pressure on healthcare systems.

A digital care pathway may improve therapy adherence and outcomes by enabling personalized, data-driven care. This study evaluates the effectiveness of a nurse-led, telemonitoring pathway for CVRM in routine practice, where patients measure their blood pressure and LDL-c levels at home. The study aims to improve risk stratification, support earlier intervention, and optimize lipid and blood pressure control, ultimately leading to better patient outcomes.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Hypertension
  • Dyslipidemia

Keywords

  • Telemonitoring
  • Lipids
  • eHealth
  • Screening
  • Telemedicine
  • Risk factor management
  • Blood pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients enrolled in the digital CVRM program will be invited to participate in this registry.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • All patients enrolled in the program (high-risk and very high-risk patients)

Exclusion criteria

Exclusion Criteria:

  • Not able to provide
  • No access to smartphone and/or tablet
  • Inability to use digital tools required for the program
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
750 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Number of patients on-target for LDL-c

    Proportion of patients achieving guideline-recommended LDL-c targets

    Time frame: Baseline and 1 year

Secondary outcomes

  1. Mean LDL-c

    The mean of LDL-c values in mmol/L, measured at-home

    Time frame: Baseline and 1 year follow-up

  2. Number of patients achieving blood pressure control

    Proportion of patients achieving guideline-recommended blood pressure targets

    Time frame: Baseline and 1 year

  3. Change in home-measured blood pressure values

    Change in blood pressure values measured at home with telemonitoring in mmHg

    Time frame: Baseline and 1 year

  4. Number of medication changes

    Changes in lipid-lowering and antihypertensive medications, defined as change in dose and change in medication type

    Time frame: 1 year

  5. 5-item Medication Adherence Report Scale (MARS-5)

    5 questions about medication adherence, with higher scores indicating better adherence

    Time frame: Baseline and 1 year

  6. Visual Analog Scale (VAS) for medication adherence

    The scale ranges from 0% to 100%, with higher scores indicating better medication adherence

    Time frame: Baseline and 1 year

  7. Quality of life (QoL)

    Using the EuroQoL-5D questionnaire

    Time frame: Baseline and 1 year

  8. Telehealth Usability Questionnaire (TUQ)

    18 questions on patient satisfaction and usability, with higher scores indicating better satisfaction

    Time frame: Baseline and 1 year

  9. Hospitalization

    Unplanned cardiovascular (re)hospitalization

    Time frame: 12 and 24 months

  10. MACE

    Cardiovascular death, myocardial infarction, any documented stroke (ischemic or hemorrhagic), ischemia-driven revascularization

    Time frame: 12 and 24 months

  11. All-cause mortality

    Total number of deaths from any cause

    Time frame: 12 and 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 145 non-industry observational studies under Atherosclerosis, half reached primary completion within 84 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 158. This study's planned 24 months is below that.

Counting every sponsor, half of 170 studies reached it within 62 months; a quarter within 31 and three quarters within 153.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Oct 2025 → Mar 2026, primary completion Oct 2027 → Mar 2028 and completion Oct 2030 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 6, 2025
StartActual
Mar 30, 2026was Oct 2025
Primary completionEst.
Mar 30, 2028was Oct 2027
CompletionEst.
Mar 30, 2030was Oct 2030
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
Cardiology Centers of the Netherlands (CCN) is now Recruiting
Oct 9, 2026
Start date
Oct 6, 2025→Mar 30, 2026 (actual)
Oct 9, 2026
Primary completion
Oct 1, 2027→Mar 30, 2028
Oct 9, 2026
Study completion
Oct 1, 2030→Mar 30, 2030
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    Cardiology Centers of the Netherlands (CCN) is now Recruiting
    Start date Oct 6, 2025→Mar 30, 2026 (now actual)
    Primary completion Oct 1, 2027→Mar 30, 2028
    Study completion Oct 1, 2030→Mar 30, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07208331
Collaborators
Cardiology Centres of the Netherlands
Responsible party
M.M. Winter (MD, PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Oct 6, 2025
Start date
Mar 30, 2026
Primary completion
Mar 30, 2028 (estimated)
Completion
Mar 30, 2030 (estimated)
Last update
Oct 9, 2026

Study contacts

Youri Schut, MSc
Contact
y.schut@amsterdamumc.nl
+31205668051

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion